Hepatitis B virus antigen (HBV antigen) (none (commonly HBV Ag, but not a canonical abbreviation for a target class))

Hepatitis B virus antigens—including the surface antigen (HBsAg), core antigen (HBcAg), and e antigen (HBeAg)—are viral proteins produced within infected hepatocytes[3][5][6]. These antigens are released or exposed following viral replication, taken up by antigen-presenting cells (APCs) such as dendritic cells, B cells, and macrophages, and then presented on human leukocyte antigen (HLA) molecules (MHC class I or II), activating HBV-specific CD4⁺ (helper) and CD8⁺ (cytotoxic) T cells[1][3][7][9]. The efficiency and character of this antigen presentation govern the outcome of infection: robust acute-phase responses lead to viral clearance, while suboptimal or tolerogenic responses result in chronic infection due to immune evasion mechanisms, typically involving HBV-driven impairment of antigen presentation and regulation of immune cell activation[2][6][9]. Therapies such as recombinant vaccines and interferons harness or modulate these antigen presentation pathways to control infection, while excessive immune recognition can cause collateral hepatic inflammation and damage[5][6][7][9]. In summary: the supplied target refers to a biological process, not a molecular entity, and is not a canonical therapeutic target. It underpins immune recognition of Hepatitis B, informing biomarker selection and vaccine strategies, but should be refined to refer to HBV antigens or a specific antigen-presenting pathway for structured target analyses.

Other names

Hepatitis B virus antigensHBV antigenHBV surface antigen (HBsAg)HBV core antigen (HBcAg)HBV e antigen (HBeAg)

Vaccines: induction of HBV-specific antibodies via APC presentation to helper T cells; Interferons: enhancement of antigen presentation, increased antiviral response; Immunotherapies: restoration of T cell recognition of infected hepatocytes